IP Library Granted Patent US 7,981,843
Granted Patent B2
US 7,981,843 · App. 11/040,159 · Granted Jul 19, 2011

Antibody specificity transfer using minimal essential binding determinants

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,981,843
App. No.
11/040,159
Granted
Jul 19, 2011
Kind
B2
Abstract

The present invention provides methods of making antibodies having the binding specificity of a reference antibody. Antibodies generated by the methods of the inventions have at least one minimal essential binding specificity determinant from a heavy chain or light chain CDR3 from the reference antibody. The method can be used, e.g., in humanization procedures. The invention also provides libraries and antibodies made in accordance with the methods.

Claims (18)

1. A method of making an antibody having a binding specificity of a reference antibody that binds to an antigen, the method comprising

a) recombinantly joining a heavy chain CDR3D segment from the reference antibody, which CDR3D segment is linked to a FR4, to an unselected member of a diverse population of human FR1-CDR1-FR2-CDR2-FR3 V H segments from human cells, thereby creating a library of V H regions that comprises members that have the reference antibody heavy chain CDR3D segment linked to diverse unselected human FR1-CDR1-FR2-CDR2-FR3 V H segments;

b) recombinantly joining a light chain CDR3BSD from the reference antibody, which reference antibody light chain CDR3BSD is linked to a Jκ germline FR4 to provide a light chain CDR3BSD-Jκ germline FR4, to an unselected member of a diverse population of human FR1-CDR1-FR2-CDR2-FR3V L segments obtained from human cells, thereby creating a library of V L regions that comprises members that have the CDR3BSD-Jκ germline FR4 linked to diverse unselected human FR1-CDR1-FR2-CDR2-FR3V L segments;

c) combining the libraries of step a and step b to create an antibody library wherein the members of the antibody library comprise a diversity of V H regions and a diversity of V L regions that have the reference antibody heavy chain CDR3D segment and the light chain CDR3BSD-Jκ germline FR4; and

d) screening the library of step c and isolating a member of the library that binds to the antigen.

2. The method of claim 1 , wherein the diverse population of human FR1-CDR1-FR2-CDR2-FR3 V H segments are human germline V H segments or the diverse population of human FR1-CDR1-FR2-CDR2-FR3 V L segments are human germline V L segments.

3. The method of claim 1 , wherein both the diverse population of human FR1-CDR1-FR2-CDR2-FR3 V H segments from human cells and the diverse population of human FR1-CDR1-FR2-CDR2-FR3 V L segments from human cells are human germline segments.

4. The method of claim 1 , wherein the diverse population of human FR1-CDR1-FR2-CDR2-FR3 V H segments is from one human FR1-CDR1-FR2-CDR2-FR3 V segment subclass.

5. The method of claim 1 , wherein the diverse population of human FR1-CDR1-FR2-CDR2-FR3 V L segments is from one human FR1-CDR1-FR2-CDR2-FR3 V segment subclass.

6. The method of claim 1 , wherein the step of isolating a member of the library of step c comprises a screening step to identify a member of the library that binds to the antigen with the same or higher affinity than the reference antibody.

7. The method of claim 1 , wherein the reference antibody is a nonhuman antibody.

8. The method of claim 1 , wherein the step of combining the libraries comprises expressing the library of V H regions and the library of V L regions on a single expression vector.

9. The method of claim 8 , wherein the V H library and the V L library are expressed using separate promoters.

10. The method of claim 1 , wherein the step of combining the libraries comprises expressing the library of V H regions and the library of V L regions on two expression vectors.

11. The method of claim 1 , wherein the human antibody library of step c) comprises antibodies where an antibody is an IgG, an Fv, an Fab, an Fab′, an F(ab′)2, a single chain Fv, or an IgG with a deletion of one or more domains.

12. The method of claim 1 , wherein the step of isolating the members of the library comprises screening using a colony lift binding assay.

13. The method of claim 1 , wherein the step of isolating the members of the library comprises screening using bacterial cell display or yeast cell display technology.

14. The method of claim 1 , wherein the step of isolating the members of the library comprises screening pools of library members.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2020
From: BLACK HORSE CAPITAL MASTER FUND LTD.
To: HUMANIGEN, INC.
Reel/Frame 052920/0631 →
SECURITY INTEREST Recorded Jul 16, 2019
From: HUMANIGEN, INC.
To: BLACK HORSE CAPITAL MASTER FUND LTD.
Reel/Frame 049769/0067 →
RELEASE OF SECURITY INTEREST Recorded Mar 30, 2018
From: BLACK HORSE CAPITAL MASTER FUND LTD.
To: KALOBIOS PHARAMECUTICALS, INC.
Reel/Frame 045788/0148 →
RELEASE OF SECURITY INTEREST Recorded Mar 30, 2018
From: BLACK HORSE CAPITAL MASTER FUND LTD.
To: KALOBIOS PHARAMECUTICALS, INC.
Reel/Frame 045855/0533 →
CHANGE OF NAME Recorded Nov 6, 2017
From: KALOBIOS PHARMACEUTICALS, INC.
To: HUMANIGEN, INC.
Reel/Frame 044377/0915 →
SECURITY INTEREST Recorded Dec 22, 2016
From: KALOBIOS PHARAMECUTICALS, INC.
To: BLACK HORSE CAPITAL MASTER FUND LTD.
Reel/Frame 041181/0605 →
SECURITY INTEREST Recorded May 23, 2016
From: KALOBIOS PHARMACEUTICALS, INC.
To: BLACK HORSE CAPITAL, LP
Reel/Frame 038788/0266 →